Novartis announced it will present new data from its oncology portfolio at the 2023 American Society of Clinical Oncology, or ASCO, Annual Meeting, including from more than 40 Novartis-sponsored and investigator-led trials. Primary results from the NATALEE trial evaluating Kisqali plus endocrine therapy, which the firm calls "the first and only positive Phase III study of a CDK4/6 inhibitor in a broad population of patients with stage II and III HR+/HER2- early breast cancer at risk of recurrence, including those with no nodal involvement," will be presented. "We look forward to sharing the primary analysis from the Phase III NATALEE trial of Kisqali in the investigational setting in a broad population of patients with early-stage breast cancer at ASCO. These promising data, together with other key updates, illustrate how we continue to advance our pipeline in oncology, with the potential to help address the significant unmet needs of patients living with cancer," said Shreeram Aradhye, M.D., President, Global Drug Development and Chief Medical Officer, Novartis.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS:
- Bristol-Myers adds new U.S. manufacturing facility for viral vector production
- Novartis announces results from Phase III APPOINT-PNH trial of iptacopan
- Novartis upgraded to Buy from Hold at Deutsche Bank
- Novartis raises FY23 group sales view to ‘mid-single digits’ from ‘low-to-mid’
- Novartis reports Q1 EPS $1.71, consensus $1.55
